Investment
Features
FeesSafety
Academy
More
Pluang+

Compare First Citizens BancShares Inc (FCNCA) vs Medpace Holdings Inc (MEDP) Price & Performance

First Citizens BancShares IncTrade
Medpace Holdings IncTrade

Price performance (Past 24H)

Key statistics

First Citizens BancShares Inc vs Medpace Holdings Inc — how do they compare? First Citizens BancShares Inc trades at $2,076.42 (market cap $22.94B), while Medpace Holdings Inc trades at $617.27 (market cap $16.82B). The key difference: First Citizens BancShares Inc is the larger of the two by market cap, and First Citizens BancShares Inc pays a 0.41% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold First Citizens BancShares Inc for 29 Days and Medpace Holdings Inc for 14 Days on average.

FCNCAMEDP
Market Cap
$22.94B$16.82B
Volume
91,668223,093
Sector
Sector/ThematicHealth
52-Week High
$2.29K$630.19
52-Week Low
$1.64K$393.42
Typical Hold Time
29 Days14 Days
Dividend Yield
0.41%—
Enterprise Value
—$16.44B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

First Citizens BancShares Inc

First Citizens BancShares (FCNCA) trades at $2,071.56, down 0.79% on the day, with a bearish technical signal driven by moving averages. The stock shows strong fundamentals, with a P/E of 11.11 and net income margin of 25.23%, and has beaten EPS estimates for the last three quarters. Recent corporate actions include a $2.10 dividend and expansion through branch acquisitions and new financing initiatives.

The outlook is mixed: solid profitability and earnings beats support upside toward the $2,290 consensus price target, but near-term technical weakness and high institutional hold ratings suggest caution. Key risks include execution of growth initiatives and broader economic pressures on banking.

Medpace Holdings Inc

MEDP trades at $604.25, up 0.22% today, with a neutral technical signal and strong fundamental performance. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results expected on October 21, 2026. Revenue grew to $2.53 billion in 2025, with a net income margin of 17.67% and robust ROE of 162.15%. Analyst consensus is a $620.44 price target, though institutional sentiment is mixed with recent CEO share sales.

Outlook remains positive given earnings momentum and projected 2026 revenue growth to $2.8 billion. Key risks include high valuation multiples and insider selling. The stock offers upside to consensus target but requires monitoring of Q3 earnings and competitive pressures in medical services.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

FCNCA

No sentiment data available yet.

MEDP
100% Buy0% Sell
Avg holding period · 14 Days

Top news

Latest headlines on both assets

About First Citizens BancShares Inc

First Citizens BancShares is a major US regional bank providing diverse financial services. It recently expanded significantly by acquiring the assets and liabilities of Silicon Valley Bank.

Read more on FCNCA →

About Medpace Holdings Inc

Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.

Read more on MEDP →